Relationship Between Amyloid Positivity and Sleep Characteristics in the Elderly With Subjective Cognitive Decline
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background and Purpose: Alzheimer’s disease (AD) is a neurodegenerative disease characterized by a progressive decline in cognition and performance of daily activities. Recent studies have attempted to establish the relationship between AD and sleep. It is believed that patients with AD pathology show altered sleep characteristics years before clinical symptoms appear. This study evaluated the differences in sleep characteristics between cognitively asymptomatic patients with and without some amyloid burden. Methods: Sleep characteristics of 76 subjects aged 60 years or older who were diagnosed with subjective cognitive decline (SCD) but not mild cognitive impairment (MCI) or AD were measured using Fitbit® Alta HR, a wristwatch-shaped wearable device. Amyloid deposition was evaluated using brain amyloid plaque load (BAPL) and global standardized uptake value ratio (SUVR) from fluorine-18 florbetaben positron emission tomography. Each component of measured sleep characteristics was analyzed for statistically significant differences between the amyloid-positive group and the amyloid-negative group. Results: Of the 76 subjects included in this study, 49 (64.5%) were female. The average age of the subjects was 70.72±6.09 years when the study started. 15 subjects were classified as amyloid-positive based on BAPL. The average global SUVR was 1.598±0.263 in the amyloid-positive group and 1.187±0.100 in the amyloid-negative group. Time spent in slow-wave sleep (SWS) was significantly lower in the amyloid-positive group (39.4±13.1 minutes) than in the amyloid-negative group (49.5±13.1 minutes) (p=0.009). Conclusions: This study showed that SWS is different between the elderly SCD population with and without amyloid positivity. How SWS affects AD pathology requires further research.
Abstract
Background and Purpose: Alzheimer’s disease (AD) is a neurodegenerative disease characterized by a progressive decline in cognition and performance of daily activities. Recent studies have attempted to establish the relationship between AD and sleep. It is believed that patients with AD pathology show altered sleep characteristics years before clinical symptoms appear. This study evaluated the differences in sleep characteristics between cognitively asymptomatic patients with and without some amyloid burden. Methods: Sleep characteristics of 76 subjects aged 60 years or older who were diagnosed with subjective cognitive decline (SCD) but not mild cognitive impairment (MCI) or AD were measured using Fitbit® Alta HR, a wristwatch-shaped wearable device. Amyloid deposition was evaluated using brain amyloid plaque load (BAPL) and global standardized uptake value ratio (SUVR) from fluorine-18 florbetaben positron emission tomography. Each component of measured sleep characteristics was analyzed for statistically significant differences between the amyloid-positive group and the amyloid-negative group. Results: Of the 76 subjects included in this study, 49 (64.5%) were female. The average age of the subjects was 70.72±6.09 years when the study started. 15 subjects were classified as amyloid-positive based on BAPL. The average global SUVR was 1.598±0.263 in the amyloid-positive group and 1.187±0.100 in the amyloid-negative group. Time spent in slow-wave sleep (SWS) was significantly lower in the amyloid-positive group (39.4±13.1 minutes) than in the amyloid-negative group (49.5±13.1 minutes) (p=0.009). Conclusions: This study showed that SWS is different between the elderly SCD population with and without amyloid positivity. How SWS affects AD pathology requires further research.
참고문헌 (27)
- Tarasoff-Conway JM, "Clearance systems in the brain-implications for Alzheimer disease", Nat Rev Neurol, 11, pp.457~470 (2015)
- Kang JE, "Amyloid-β dynamics are regulated by orexin and the sleep-wake cycle", Science, 326, pp.1005~1007 (2009)
- Vodovotz Y, "Prioritized research for the prevention, treatment, and reversal of chronic disease : recommendations from the lifestyle medicine research summit", Front Med(Lausanne), 7, pp.585744~ (2020)
- Reddy OC, "The sleeping brain : harnessing the power of the glymphatic system through lifestyle choices", Brain Sci, 10, pp.868~ (2020)
- Wang C, "Bidirectional relationship between sleep and Alzheimer’s disease : role of amyloid, tau, and other factors", Neuropsychopharmacology, 45, pp.104~120 (2020)
- Jessen F, "The characterisation of subjective cognitive decline", Lancet Neurol, 19, pp.271~278 (2020)
- Reisberg B, "The pre-mild cognitive impairment, subjective cognitive impairment stage of Alzheimer’s disease", Alzheimers Dement, 4(Suppl 1), pp.S98~S108 (2008)
- Parnetti L, "Prevalence and risk of progression of preclinical Alzheimer’s disease stages : a systematic review and meta-analysis", Alzheimers Res Ther, 11, pp.7~ (2019)
- Jansen WJ, "Prevalence of cerebral amyloid pathology in persons without dementia : a meta-analysis", JAMA, 313, pp.1924~1938 (2015)
- Ho S, "Study design and baseline results in a cohort study to identify predictors for the clinical progression to mild cognitive impairment or dementia from subjective cognitive decline(CoSCo)study", Dement Neurocogn Disord, 21, pp.147~161 (2022)
- Petersen RC, "Mild cognitive impairment as a diagnostic entity", J Intern Med, 256, pp.183~194 (2004)
- Hong YJ, "Predictors of clinical progression of subjective memory impairment in elderly subjects : data from the Clinical Research Centers for Dementia of South Korea(CREDOS)", Dement Geriatr Cogn Disord, 40, pp.158~165 (2015)
- Barthel H, "Cerebral amyloid-β PET with florbetaben(18F)in patients with Alzheimer’s disease and healthy controls : a multicentre phase 2 diagnostic study", Lancet Neurol, 10, pp.424~435 (2011)
- Lyoo CH, "Cerebellum can serve as a pseudo-reference region in Alzheimer’s disease to detect neuroinflammation measured with PET radioligand binding to translocator protein(TSPO)", J Nucl Med, 56, pp.701~706 (2015)
- Fonseca P, "Sleep stage classification with ECG and respiratory effort", Physiol Meas, 36, pp.2027~2040 (2015)
- Spira AP, "Self-reported sleep and β-amyloid deposition in community-dwelling older adults", JAMA Neurol, 70, pp.1537~1543 (2013)
- Ooms S, "Effect of 1 night of total sleep deprivation on cerebrospinal fluid β-amyloid 42 in healthy middle-aged men : a randomized clinical trial", JAMA Neurol, 71, pp.971~977 (2014)
- Shokri-Kojori E, "β-Amyloid accumulation in the human brain after one night of sleep deprivation", Proc Natl Acad Sci U S A, 115, pp.4483~4488 (2018)
- Ju YS, "Slow wave sleep disruption increases cerebrospinal fluid amyloid-β levels", Brain, 140, pp.2104~2111 (2017)
- Lee YF, "Slow wave sleep is a promising intervention target for Alzheimer’s disease", Front Neurosci, 14, pp.705~ (2020)
- Westerberg CE, "Concurrent impairments in sleep and memory in amnestic mild cognitive impairment", J Int Neuropsychol Soc, 18, pp.490~500 (2012)
- Olsson M, "Sleep deprivation and cerebrospinal fluid biomarkers for Alzheimer’s disease", Sleep (Basel), 41, pp.zsy025~ (2018)
- Livingston G, "Dementia prevention, intervention, and care : 2020 report of the Lancet Commission", Lancet, 396, pp.413~446 (2020)
- Ngandu T, "A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people(FINGER) : a randomised controlled trial", Lancet, 385, pp.2255~2263 (2015)
- Livingston G, "Dementia prevention, intervention, and care", Lancet, 390, pp.2673~2734 (2017)
- Beattie Z, "Estimation of sleep stages using cardiac and accelerometer data from a wrist-worn device", Sleep, 40(Supple 1), pp.A26~ (2017)
- Chinoy ED, "Performance of seven consumer sleep-tracking devices compared with polysomnography", Sleep (Basel), 44, pp.zsaa291~ (2021)